Facts and Figures

Rankings

Biomedical engineering at Texas A&M University has been a degree-granting program since 1972 and has been ABET-accredited since 1977. The department's undergraduate program is ranked 12th and the graduate program is ranked 18th among public institutions by U.S. News & World Report.

$23M in external research funding

FY2021

26 faculty researchers Faculty directory

Faculty researchers on staff from 2021-2022

Student Enrollment

Enrollment (Fall 2022)
Student Level	Number of Students
Undergraduate	493
Master's	52
Doctoral	114
Total Enrollment	659
Source: Texas A&M University Data and Research Services As reported to the Texas Higher Education Coordinating Board.

Degrees Awarded

Degrees Awarded (Fall 2021, Spring 2022 and Summer 2022)
Degree Level	Number of Degrees Awarded
Bachelor's	149
Master's	30
Doctoral	18
Total Degrees Awarded	197
Source: Texas A&M University Data and Research Services

Diversity

Undergraduate - 48% female, 27% minority
Graduate - 44% female, 15% minority

Faculty

Our faculty members are involved in research from the macroscopic to the nanoscale in the areas of diagnostic and therapeutic systems, imaging systems, soft and hard tissue biomechanics, tissue characterizations, biomaterials used in the human body, orthopedic biomechanics, FDA regulatory practices, bioinstrumentation, measurement and analysis of human body signals, and analysis of the interaction between humans and medical devices. In addition, they have strong collaborations with medical and veterinary schools as well as various other departments throughout the university and around the world.

Faculty (Fall 2021)
Tenure Status	Number of Faculty
Tenured/Tenure-Track	26
Academic Professional Track	10
Total Faculty	36

Faculty Recognition

Five Endowed Professorships
29 editorships and editorial board memberships
12 Fellow grades in professional societies

Our research has resulted in new patents, new companies and new economic activity. With increasing demands for quality medical devices, procedures and improved cost-effectiveness, we are positioned to lead the way in the development, testing and commercialization of products, systems and technologies.

$23M in external research funding (FY2021)
65 patents filed
38 disclosures filed
11 start-up companies created, including one exit through acquisition by Medtronic, Inc.
12 Invention Disclosures submitted and 20 Patents issued (US and non-US combined)